Tracker › Companies › Neumora Therapeutics, Inc.
3 No sign of it. We found no public evidence tying Neumora Therapeutics, Inc.'s cuts to AI.
Every tracked 2026 layoff at Neumora Therapeutics, Inc., newest first. Scores are 0–100: how strongly the public evidence ties the cuts to AI. Sources are linked on each one.
AI score 3/100 (Minimal) · 80% interval 2–4 · evidence grade D · US · Pharma / Chemicals
Stated reason: On June 12, 2026, in connection with the discontinuation of development of navacaprant described below, the Company implemented a reduction in force of approximately 35%, which it expects to complete in the second and third quarters of 2026. The Company expects the reduction in force to result in an annualized cost savings of approximately $10 million, partially offset by one-time restructuring costs of approximately…
Why 3: Plant, store or site closure · Drivers: contrary evidence −0.7, industry AI exposure +0.5
Evidence: SEC filing. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.888, industry exposure 0.712, AI investment 0.0, contrary evidence 0.4 · named roles: Computer Systems Analysts, Data Scientists, Software Developers
Headcount basis: not disclosed
Scores are evidence-based estimates from a published model, not findings that AI caused any layoff. Spot something wrong or missing? Tell us.
Other Health Care & Pharma layoffs we track.
Health Care & Pharma · 3,800 workers
Health Care & Pharma · 648 workers
Health Care & Pharma · 419 workers
Health Care & Pharma · 365 workers
Health Care & Pharma · 300 workers
Health Care & Pharma · 120 workers
